X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (627) 627
Patent (211) 211
Conference Proceeding (41) 41
Publication (13) 13
Book Review (12) 12
Dissertation (2) 2
Book / eBook (1) 1
Book Chapter (1) 1
Streaming Audio (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (303) 303
humans (279) 279
male (233) 233
female (218) 218
oncology (206) 206
middle aged (182) 182
aged (173) 173
adult (170) 170
physics (107) 107
cancer (94) 94
chemotherapy (77) 77
treatment outcome (75) 75
performing operations (73) 73
transporting (73) 73
medicine & public health (65) 65
colorectal cancer (60) 60
analysis (57) 57
antineoplastic combined chemotherapy protocols - therapeutic use (57) 57
pharmacology & pharmacy (52) 52
cancer research (51) 51
cinematography (50) 50
electrography (50) 50
electrophotography (50) 50
holography (50) 50
magnetography (50) 50
photography (50) 50
aged, 80 and over (49) 49
stomach neoplasms - drug therapy (49) 49
colorectal neoplasms - drug therapy (47) 47
japan (47) 47
fluorouracil (45) 45
care and treatment (44) 44
neoplasms - drug therapy (44) 44
prognosis (44) 44
camptothecin - analogs & derivatives (41) 41
research (41) 41
stomach neoplasms - pathology (41) 41
expression (40) 40
gastric cancer (40) 40
animals (39) 39
colorectal neoplasms - pathology (37) 37
retrospective studies (37) 37
tumors (36) 36
disease-free survival (35) 35
pharmacology/toxicology (35) 35
metastasis (34) 34
antineoplastic agents - therapeutic use (33) 33
drug administration schedule (33) 33
fluorouracil - administration & dosage (33) 33
irinotecan (33) 33
camptothecin - administration & dosage (32) 32
chemistry (32) 32
metallurgy (32) 32
neoplasm staging (32) 32
stomach cancer (32) 32
dose-response relationship, drug (30) 30
antineoplastic combined chemotherapy protocols - adverse effects (29) 29
cisplatin (29) 29
therapy (29) 29
antimitotic agents (28) 28
antineoplastic agents (28) 28
neurosciences (28) 28
surgical oncology (28) 28
trial (28) 28
5-fluorouracil (27) 27
leucovorin (27) 27
neoplasm metastasis (27) 27
oxaliplatin (27) 27
drug combinations (26) 26
electricity (26) 26
antineoplastic agents - adverse effects (25) 25
asian continental ancestry group (25) 25
maximum tolerated dose (25) 25
medical research (25) 25
oncology, experimental (25) 25
carcinoma (24) 24
pharmacokinetics (24) 24
cancer patients (23) 23
haplotypes (23) 23
polymorphism, single nucleotide (23) 23
psychiatry (23) 23
surgery (23) 23
tegafur - administration & dosage (23) 23
bevacizumab (22) 22
child (22) 22
genetic aspects (22) 22
infusions, intravenous (22) 22
mutation (22) 22
oxonic acid - administration & dosage (22) 22
alloys (21) 21
breast-cancer (21) 21
cell line, tumor (21) 21
counting (21) 21
ferrous or non-ferrous alloys (21) 21
genotype (21) 21
s-1 (21) 21
survival (21) 21
treatment of alloys or non-ferrous metals (21) 21
antineoplastic agents - administration & dosage (20) 20
asian continental ancestry group - genetics (20) 20
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (807) 807
Japanese (48) 48
French (26) 26
German (16) 16
Chinese (5) 5
Portuguese (2) 2
Korean (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1278 - 1286
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2014, Volume 9, Issue 4, pp. e92921 - e92921
Journal Article
Gastric Cancer, ISSN 1436-3291, 10/2015, Volume 18, Issue 4, pp. 824 - 832
This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone... 
Irinotecan | Anti-EGFR | Medicine & Public Health | Gastroenterology | Second-line therapy | Abdominal Surgery | Oncology | Cancer Research | Surgical Oncology | Advanced gastric cancer | Nimotuzumab | ADVANCED ESOPHAGOGASTRIC CANCER | MONOCLONAL-ANTIBODY H-R3 | CHEMOTHERAPY PLUS | CELL LUNG-CANCER | CAPECITABINE | GROWTH-FACTOR RECEPTOR | SUPPORTIVE CARE | CISPLATIN | ONCOLOGY | EGFR ANTIBODY | 1ST-LINE THERAPY | GASTROENTEROLOGY & HEPATOLOGY | Immunohistochemistry | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Antibodies, Monoclonal, Humanized - administration & dosage | DNA Mutational Analysis | Polymerase Chain Reaction | Adult | Camptothecin - administration & dosage | Female | Adenocarcinoma - genetics | Camptothecin - analogs & derivatives | Genes, ras - genetics | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Receptor, Epidermal Growth Factor - biosynthesis | Receptor, ErbB-2 - biosynthesis | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Stomach Neoplasms - mortality | Salvage Therapy - methods | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Cancer patients | Clinical trials | Product development | Antineoplastic agents | Stomach cancer | Cancer | Index Medicus | Original
Journal Article
International Urogynecology Journal, ISSN 0937-3462, 2019, pp. 1 - 6
The steep Trendelenburg position, high pneumoperitoneum pressure, and longer surgical time may lead to significantly increased intraocular pressure (IOP),... 
Glaucoma | Laparoscopic sacral colpopexy | Pelvic organ prolapse | Trendelenburg | Intraocular pressure | Eye diseases | Laparoscopy | Patients | Surgery
Journal Article
Molecular Cancer, ISSN 1476-4598, 02/2019, Volume 18, Issue 1, pp. 19 - 19
Journal Article
Gastric Cancer, ISSN 1436-3291, 7/2017, Volume 20, Issue 4, pp. 655 - 662
Journal Article
Cancer Science, ISSN 1347-9032, 01/2018, Volume 109, Issue 1, pp. 193 - 198
The cyclin D ‐ CDK 4/6‐ INK 4‐Rb pathway is frequently dysregulated in cancers. Ribociclib, an orally available, selective CDK 4/6 inhibitor, showed... 
dose escalation | advanced solid tumors | phase 1 | Japanese patients | ribociclib | TRIALS | INHIBITION | THERAPY | CDK4/6 | ONCOLOGY | CANCER | Medicine, Experimental | Medical research | Lymphomas | Cancer | Index Medicus | Original
Journal Article